Medtronic has acquired certain nano surface technology assets and rights to Nanovis’ OsteoSync titanium pads. Medtronic plans to use them to develop its next-generation PEEK interbody fusion devices.

The U.S. Food and Drug Administration (FDA)-designation bone-growth nanotechnology has been demonstrated to improve the speed and consistency of the human bone-growth response, the company said. It bolsters implant fixation via osseointegration, the process where bone grows and fuses with the implant surface.

“We are excited about our collaboration with Medtronic,” said Brian More, CEO of Nanovis. “Combining our market-leading nano surface technology with Medtronic’s market-leading PEEK implant designs will give a growing number of surgeons access to best-in-class devices to treat patients.”

Nanovis was the first to market with an FDA nanotechnology designation on an enhanced PEEK interbody, which includes porous titanium endplates made from OsteoSync (provided by Sites Medical) and the first to market with an FDA nanotechnology designation on pedicle screws.

“This collaboration is a testament to the significance of the nano surface technology we developed and the value it delivers to our customers and to patients,” said More. “Medtronic’s commitment to innovation and commercial scale makes them an ideal partner to take these technologies to market.”

At last year’s North American Spine Society (NASS) meeting, Medtronic launched several software, hardware, and imaging innovations for its AiBLE smart ecosystem. AiBLE is comprised of navigation, robotics, data and artificial intelligence (AI), imaging, software, and implants for spine and cranial procedures.